Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

20 June 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Bretaris Genuair Articles

Positive Ph III results for Almirall and Forest's combination COPD drug

16 April 2013

Added benefit of Almirall's aclidinium bromide is not proven, says Germany's IQWiG

10 January 2013

Almirall's aclidinium approved in Europe for COPD maintenance treatment

25 July 2012

Europe's CHMP issues positive opinions on aclidinium, Fycompa, Inlyta and NovoThirteen

27 May 2012

Showing 1-4 of 4 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Takeda debuts three new diabetes drugs, Nesina, Kazano and Oseni, in USA
  • Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
  • Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
  • It's official: "obesity is a disease," says AMA
  • Mixed results for AstraZeneca/B-MS' Onglyza; Newron's safinamide does well in PD
  • Takeda debuts three new diabetes drugs, Nesina, Kazano and Oseni, in USA
  • Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
  • Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
  • It's official: "obesity is a disease," says AMA
  • Mixed results for AstraZeneca/B-MS' Onglyza; Newron's safinamide does well in PD

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS